This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.
Age ≥ 18 years old, gender is not limited;
Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;
Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.
Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;
With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;
Gastrointestinal disease with active bleeding;
Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;